Confirmed Sponsors
Platin Sponors
Gold Sponsors
Silver Sponors
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Our technologies are categorized into our four business units - heart valve therapy, critical care, cardiac surgery systems and vascular – each with a rich history and unique patient focus. We also lead the development of new investigative technologies designed for the non-surgical replacement of heart valves and minimal invasive cardiovascular techniques. We believe that these challenging new procedures hold great promise for patients considered high-risk for conventional valve replacement as this technology allows clinicians to deliver valves via a catheter, eliminating the need for traditional open-heart surgery. |
||
As a trusted partner for hospitals and clinicians since 1838, Maquet is a global leader in medical systems that advance surgical interventions, cardiovascular procedures and critical care. Maquet develops and designs innovative products and therapeutic applications for the operating room, hybrid OR/cathlab, intensive care unit, and patient transport within acute care hospitals, improving outcomes and quality of life for patients. MAQUET – The Gold Standard. For more information please visit www.maquet.com and www.getingegroup.com. |
||
The Nikkiso group has been providing extracorporeal technologies and products in order to meet demands of our customer and patients, the society and the times we live in for more than half a century. We are recognized as precision machinery company in the field of blood purification and hemodialysis. Beside our huge expertise in the development and production of technology and medical equipment our R&D team recently developed a new adsorptive device for the treatment of Ulcerative Colitis patients. Based in Hanover/Germany the Nikkiso Europe is responsible for the development, production and sales of Nikkiso products in the EMEA region. |
||
Miltenyi Biotec, founded in 1989, is a premier provider of advanced products and services in the fields of stem cells, immune and cellular therapies as well as tissue regeneration. With more than 1200 employees worldwide, we develop, manufacture and commercialize state-of the-art technologies for research and clinical applications. Our products and services cover all areas of cell-based research and clinical development, from sample preparation, cell separation, cell culture, flow cytometric and molecular analysis, to clinical therapeutic applications and contract GMP manufacturing. | ||
CytoSorbents is a medtech company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its technology is based on biocompatible, highly porous polymer beads that can remove toxic substances from blood by pore capture and adsorption. In 2011, CytoSorb® achieved CE approval as an extracorporeal cytokine filter to be used in patients with elevated cytokines. CytoSorb® modulates the immune system by reducing "cytokine storm" that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in illnesses such as sepsis, trauma, burn injury, ARDS, pancreatitis amd other systemic inflammatory syndromes. CytoSorb filters are commercially available in Germany, Austria, Switzerland and selected European countries. | ||
Since 2006 HepaNet is responsible in the field of liver dialysis business in Germany, representing the Albumin-Dialysis. Besides the classical sale of consumables HepaNet draws from our individual therapy service in case of emergency. We also offer since 2011 pocket ultrasonic devices from GE Healthcare. | ||
The SynCardia temporary Total Artificial Heart (TAH-t) is the world’s only FDA, Health Canada and CE approved Total Artificial Heart. The TAH-t is currently approved as a bridge to transplant for patients dying from end-stage biventricular failure. The 13.5 lb Freedom™ portable driver has received CE approval in Europe and is undergoing an IDE clinical study in the U.S. The Freedom driver is designed to provide mobility for stable TAH-t patients both inside and outside the hospital. Visit our booth for updates on the clinical study, the 50cc TAH-t and destination therapy. | ||
Kaneka Pharma Europe N.V is the major enterprise in developing and commercializing medical devices as vascular intervention and therapeutic apharesis products, functional food ingredients as Co-Q10 and pharmaceutical ingredients for mainly statins and ACE-i for the healthcare sector. This combination and our long experience in those fields make it possible, that Kaneka is the expert in successfully supporting the CVD management interventions. |